Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“VIKTORIA-1 published in JCO, showing promising activity of fulvestrant/gedatolisib +/-palbo in PIK3CAwt HR+ MBC, at the expense of weekly IV injections (3week on 1week off) and most patients experiencing stomatitis.
2 treatment-related deaths with the triplet.”
Title: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
Authors: Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Sung-Bae Kim, Jorge Luis Martínez Rodríguez, Jorge C. Nadal, Gun Min Kim, Louisa Lo, Yuly A. Remolina-Bonilla, Geronimo Rosselli, George Emile, Ernesto Korbenfeld, Juan Manuel Puig, Robert Wesolowski, Miguel Martin, Alistair Ring, Hyo S. Han, Antonio Giordano, Sarah C. Mutka, Keren Moss, Sam Suzuki, Brian Sullivan, Igor Gorbatchevsky, Barbara Pistilli
Read The Full Article
Other articles about Breast Cancer on OncoDaily.